| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Dividendenbekanntmachungen (20.02.2026) | 5.691 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ASX LIMITED AU000000ASX7 1,018 AUD 0,6103 EUR ATMUS FILTRATION TECHNOLOGIES INC US04956D1072 0,055 USD 0,0467 EUR AUDIOCODES LTD IL0010829658 0... ► Artikel lesen | |
| 13:15 | Bayer Aktie: Alles vorbei? - Airbus, BB Biotech, BioNTech, TUI und Valneva - Börse Frankfurt | 670 | 4investors | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| 07:49 | Validierte Exosomen-Chargen, klarer Fahrplan: Wie NurExone Biologic Schritt für Schritt Richtung Klinik voranschreitet | Small- & Micro Cap Investment | |||
| Fr | Blitz-Update: Dow & Co uneinheitlich - Amazon, Salesforce, Apple stark, Chemours, Grail sacken ... | 494 | Der Aktionär | Die US-Börsen finden im frühen Handel am Freitag keine einheitliche Richtung. Der Leitindex Dow Jones Industrial verliert 0,3 Prozent auf 49.243,25 Zähler. Der marktbreite S&P 500 legt hingegen 0,1... ► Artikel lesen | |
| Fr | Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates | 447 | GlobeNewswire (Europe) | 2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions... ► Artikel lesen | |
| 07:48 | FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment | 382 | AFX News | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration... ► Artikel lesen | |
| 12:03 | EQS-News: ABIVAX: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 | 354 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Study results
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory... ► Artikel lesen | |
| Fr | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Approval of BYSANTI (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation | 333 | PR Newswire | WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved... ► Artikel lesen | |
| Fr | Burcon NutraScience Corporation: Burcon Announces Results of Shareholder Meeting | 309 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 20, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| Fr | Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults | 289 | Business Wire | Olanzapine long-acting injectable suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help... ► Artikel lesen | |
| 01:54 | Rakovina Therapeutics Inc: Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million | 282 | GlobeNewswire (Europe) | Proposed $1.0 Million Convertible Debenture and Warrant Financing and Concurrent Common Share Private Placement Up to $1.0 Million Intended to Support Near-Term Operations VANCOUVER, British Columbia... ► Artikel lesen | |
| Fr | Exact Sciences Corporation Stockholders Approve Acquisition by Abbott Laboratories | 176 | Business Wire | MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) ("Exact Sciences"), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted... ► Artikel lesen | |
| Fr | Psyence Biomedical Ltd.: Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment | 91 | GlobeNewswire (Europe) | NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| Fr | Trinity Biotech plc: Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares | 75 | GlobeNewswire (Europe) | DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable... ► Artikel lesen | |
| Fr | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option | 73 | GlobeNewswire (Europe) | VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| CSL | 91,50 | 2,71 | +2,96 % | 1,84 | 10.03.2026 | |
| AMGEN | 318,35 | 8,12 | +2,55 % | 2,52 | 13.02.2026 | |
| STRYKER | 322,60 | 2,89 | +0,90 % | 0,88 | 31.03.2026 | |
| BIO-TECHNE | 50,000 | 0,27 | +0,54 % | 0,08 | 13.02.2026 | |
| REGENERON PHARMACEUTICALS | 660,00 | 3,02 | +0,46 % | 0,94 | 20.02.2026 | |
| SARTORIUS STEDIM BIOTECH | 183,40 | 0,69 | +0,38 % | 0,69 | 31.03.2026 | |
| BIOGEN | 162,55 | 0,00 | 0,00 % | |||
| ENZO BIOCHEM | 0,388 | 0,00 | 0,00 % | |||
| MYRIAD GENETICS | 3,640 | 0,00 | 0,00 % | |||
| TRANSGENE | 0,782 | 0,00 | 0,00 % |